Lucia, a leader in health AI and patient engagement solutions, and the Heart Rhythm Society (HRS), the international leader ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rezolute (RZLT – Research Report) and Pfizer (PFE – Research ...
The pilot phase, sponsored by the BMS-Pfizer Alliance, is set to begin shortly, with full-scale implementation to follow based on its success. The Heart Rhythm Society is the international leader ...
Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking ...
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
News Medical on MSN8d
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancerPatients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with ...
Key ASCO GU Presentations Prostate Cancer Bladder Cancer Additional information on key Pfizer-sponsored abstracts at ASCO GU 2025, including date and time of presentation, follow in the chart below.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback